Marketdash
Back to News

Pasithea Therapeutics Soars Over 100% on ALS Grant and Clinical Trial Progress

MarketDash Editorial Team
12 days ago
Pasithea Therapeutics shares surged over 100% Wednesday as investors digested a rapid-fire series of positive updates on its lead drug candidate, including a $1 million ALS Association grant and encouraging clinical trial data.

Pasithea Therapeutics Corp (KTTA) is having a moment. Shares exploded over 100% Wednesday morning after the company delivered what amounts to a trifecta of good news about its lead drug candidate, PAS-004. The cherry on top? A fresh $1 million grant from the ALS Association that expands the drug's potential reach into a third serious neurological condition.

What's Driving the Rally

The Hoffman ALS Clinical Trial Award will bankroll a clinical study testing whether PAS-004 works in patients with amyotrophic lateral sclerosis, a devastating neurodegenerative disease. That's important because it broadens the drug's addressable market beyond its current focus areas, and the funding is non-dilutive, meaning Pasithea doesn't have to issue more shares to pay for the research.

But the ALS news is just the latest in a three-day winning streak for Pasithea. On Monday, the company announced completion of Cohort 7 in its ongoing Phase 1 trial for advanced solid tumors. The results were encouraging: no treatment-related adverse events, dose-proportional pharmacokinetics, and pharmacodynamic data consistent with continuous MAPK pathway suppression. Translation: the drug appears safe at this dose level and seems to be doing what it's designed to do. The safety committee gave the green light to move forward to Cohort 8.

Then on Friday, Pasithea shared positive pharmacokinetic data from a separate Phase 1/1b study in adult patients with NF1, a genetic disorder. A new tablet formulation delivered better drug exposure than the capsule version at lower doses, with less variability between patients. That's the kind of improvement that can make a real difference in drug development, potentially making dosing more predictable and effective.

The Reality Check

Before anyone gets too excited, it's worth remembering that PAS-004 remains in early-stage development. Regulatory approval is still years away, and plenty can go wrong between Phase 1 trials and an FDA green light. That said, the rapid succession of positive data points and the external validation from the ALS Association's funding decision have clearly shifted investor sentiment. Markets love momentum, and Pasithea delivered exactly that this week.

Price Action

Pasithea Therapeutics shares were up 118% at $1.42 at the time of publication Wednesday.

Back to News

Pasithea Therapeutics Soars Over 100% on ALS Grant and Clinical Trial Progress

MarketDash Editorial Team
12 days ago
Pasithea Therapeutics shares surged over 100% Wednesday as investors digested a rapid-fire series of positive updates on its lead drug candidate, including a $1 million ALS Association grant and encouraging clinical trial data.

Pasithea Therapeutics Corp (KTTA) is having a moment. Shares exploded over 100% Wednesday morning after the company delivered what amounts to a trifecta of good news about its lead drug candidate, PAS-004. The cherry on top? A fresh $1 million grant from the ALS Association that expands the drug's potential reach into a third serious neurological condition.

What's Driving the Rally

The Hoffman ALS Clinical Trial Award will bankroll a clinical study testing whether PAS-004 works in patients with amyotrophic lateral sclerosis, a devastating neurodegenerative disease. That's important because it broadens the drug's addressable market beyond its current focus areas, and the funding is non-dilutive, meaning Pasithea doesn't have to issue more shares to pay for the research.

But the ALS news is just the latest in a three-day winning streak for Pasithea. On Monday, the company announced completion of Cohort 7 in its ongoing Phase 1 trial for advanced solid tumors. The results were encouraging: no treatment-related adverse events, dose-proportional pharmacokinetics, and pharmacodynamic data consistent with continuous MAPK pathway suppression. Translation: the drug appears safe at this dose level and seems to be doing what it's designed to do. The safety committee gave the green light to move forward to Cohort 8.

Then on Friday, Pasithea shared positive pharmacokinetic data from a separate Phase 1/1b study in adult patients with NF1, a genetic disorder. A new tablet formulation delivered better drug exposure than the capsule version at lower doses, with less variability between patients. That's the kind of improvement that can make a real difference in drug development, potentially making dosing more predictable and effective.

The Reality Check

Before anyone gets too excited, it's worth remembering that PAS-004 remains in early-stage development. Regulatory approval is still years away, and plenty can go wrong between Phase 1 trials and an FDA green light. That said, the rapid succession of positive data points and the external validation from the ALS Association's funding decision have clearly shifted investor sentiment. Markets love momentum, and Pasithea delivered exactly that this week.

Price Action

Pasithea Therapeutics shares were up 118% at $1.42 at the time of publication Wednesday.